Daria D. Ladyko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daria D. Ladyko has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Kirill A. Turupaev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - Vsevolod Borisovich Matveev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - Aleksey V. Klimov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - A. K. Tsutsaev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication - A. V. Sarkisyan
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication - A. V. Smirnova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication
Latest Publications
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 44-53
Nirogacestat in treatment of patients with desmoid tumors. Literature review
This literature review analyzes the role of the gamma-secretase inhibitor nirogacestat in treating patients with progressive desmoid tumors. The article systematizes data on the molecular mechanisms of the drug's action, stages of its clinical development, and the final results of the phase III DeFi trial, which formed the basis for nirogacestat's regulatory approval. It is shown that the drug significantly improves progression-free survival, increases objective response rate, and leads to clinically meaningful improvement in quality of life. The review discusses nirogacestat's safety profile in detail, highlighting a specific yet reversible adverse event – ovarian dysfunction. The analyzed data provide evidence for the efficacy and safety of nirogacestat, supporting its consideration as a new therapeutic option for patients with progressive desmoid fibromatosis.
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 44-53
Nirogacestat in treatment of patients with desmoid tumors. Literature review
This literature review analyzes the role of the gamma-secretase inhibitor nirogacestat in treating patients with progressive desmoid tumors. The article systematizes data on the molecular mechanisms of the drug's action, stages of its clinical development, and the final results of the phase III DeFi trial, which formed the basis for nirogacestat's regulatory approval. It is shown that the drug significantly improves progression-free survival, increases objective response rate, and leads to clinically meaningful improvement in quality of life. The review discusses nirogacestat's safety profile in detail, highlighting a specific yet reversible adverse event – ovarian dysfunction. The analyzed data provide evidence for the efficacy and safety of nirogacestat, supporting its consideration as a new therapeutic option for patients with progressive desmoid fibromatosis.
- 21 December 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (4) , 99-106
Endosalpingiosis of the bladder. Clinical observation and literature analysis
We present a rare clinical observation of histologically confirmed endosalpingiosis of the bladder in a female patient aged 44 years who underwent combination treatment. This observation is the 8th documented case of isolated endosalpingiosis of the bladder in the world. The article demonstrates the rarity of endosalpingiosis of the bladder, complexity of differential diagnosis of this disease, and the necessity of comprehensive examination with mandatory accurate tumor histogenesis prior to determination of treatment tactics in patients with bladder neoplasms.
- 21 December 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (4) , 99-106
Endosalpingiosis of the bladder. Clinical observation and literature analysis
We present a rare clinical observation of histologically confirmed endosalpingiosis of the bladder in a female patient aged 44 years who underwent combination treatment. This observation is the 8th documented case of isolated endosalpingiosis of the bladder in the world. The article demonstrates the rarity of endosalpingiosis of the bladder, complexity of differential diagnosis of this disease, and the necessity of comprehensive examination with mandatory accurate tumor histogenesis prior to determination of treatment tactics in patients with bladder neoplasms.
- Open Access
- 17 July 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (2) , 122-128
Renal cell carcinoma associated with von Hippel–Lindau syndrome: an ambispective study
Background. Renal cell carcinoma (RCC) associated with von Hippel-Lindau syndrome (VHL) is characterized by multifocal bilateral involvement of the renal parenchyma and is the leading cause of death in this category of patients due to disease progression or the development of end-stage chronic kidney disease. Aim. To analyze the treatment outcomes of patients with RCC associated with VHL syndrome. Materials and methods. The ambispective study included data of 30 patients treated with VHL-associated RCC from 2016 to 2024. In 23 (76.7%) cases, VHL syndrome was classified as type 1, and in 7 (23.3%) as type 2B. Non-metastatic RCC at the initial diagnosis was detected in 28 (93.3%) patients and metastatic RCC in 2 (6.7%). Extrarenal manifestations of VHL syndrome occurred in all patients. Watchful waiting was used in 6 (20.0%) patients, surgical treatment of renal parenchyma tumors in 21 (70.0%), metastasectomy – in 2 (6.7%), and systemic antitumor therapy in 3 (10.0%). Treatment of extrarenal manifestations of VHL syndrome included surgical interventions in 20 (66.7%) patients, radiation therapy in 8 (26.7%), and laser therapy in 9 (30.0%). The median follow-up for all patients from the RCC detection was 46.6 [1-249.5] months. Results. The four-year overall (OS) and disease-specific (DSS) survival rates for all 30 patients were 93.3% and 93.3%, respectively. In 28 patients with primary non-metastatic RCC, the 4-year metastasis-free survival (MFS) was 74.2%. In 21 patients after radical surgery for the primary non-metastatic renal cell carcinoma, the 4-year OS was 88.9%, DSS was 88.9%, relapse-free survival (RFS) was 62.9%, local recurrence-free survival was 53.9%, and MFS was 63.6%. In patients with distant metastases, the 4-year OS was 66.7%. Two (6.7%) patients developed terminal chronic kidney disease requiring permanent hemodialysis. Conclusion. VHL-associated RCC is a chronic disease with a torpid course, allowing to recommend organ-sparing treatment of primary tumors and metastasis-directed therapy of oligometastases. Antiangiogenic therapy is effective in metastatic RCC.
- 17 July 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (2) , 122-128
Open AccessRenal cell carcinoma associated with von Hippel–Lindau syndrome: an ambispective study
Background. Renal cell carcinoma (RCC) associated with von Hippel-Lindau syndrome (VHL) is characterized by multifocal bilateral involvement of the renal parenchyma and is the leading cause of death in this category of patients due to disease progression or the development of end-stage chronic kidney disease. Aim. To analyze the treatment outcomes of patients with RCC associated with VHL syndrome. Materials and methods. The ambispective study included data of 30 patients treated with VHL-associated RCC from 2016 to 2024. In 23 (76.7%) cases, VHL syndrome was classified as type 1, and in 7 (23.3%) as type 2B. Non-metastatic RCC at the initial diagnosis was detected in 28 (93.3%) patients and metastatic RCC in 2 (6.7%). Extrarenal manifestations of VHL syndrome occurred in all patients. Watchful waiting was used in 6 (20.0%) patients, surgical treatment of renal parenchyma tumors in 21 (70.0%), metastasectomy – in 2 (6.7%), and systemic antitumor therapy in 3 (10.0%). Treatment of extrarenal manifestations of VHL syndrome included surgical interventions in 20 (66.7%) patients, radiation therapy in 8 (26.7%), and laser therapy in 9 (30.0%). The median follow-up for all patients from the RCC detection was 46.6 [1-249.5] months. Results. The four-year overall (OS) and disease-specific (DSS) survival rates for all 30 patients were 93.3% and 93.3%, respectively. In 28 patients with primary non-metastatic RCC, the 4-year metastasis-free survival (MFS) was 74.2%. In 21 patients after radical surgery for the primary non-metastatic renal cell carcinoma, the 4-year OS was 88.9%, DSS was 88.9%, relapse-free survival (RFS) was 62.9%, local recurrence-free survival was 53.9%, and MFS was 63.6%. In patients with distant metastases, the 4-year OS was 66.7%. Two (6.7%) patients developed terminal chronic kidney disease requiring permanent hemodialysis. Conclusion. VHL-associated RCC is a chronic disease with a torpid course, allowing to recommend organ-sparing treatment of primary tumors and metastasis-directed therapy of oligometastases. Antiangiogenic therapy is effective in metastatic RCC.
- Open Access
- 1 December 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (4) , 55-59
Metastasis-directed therapy for metachronous metastases of prostate cancer
Background. The main method of treatment of metastatic hormone-sensitive prostate cancer (mHSPC) is drug therapy (hormone therapy, chemotherapy). However, a special category of patients with oligometastatic lesions can be identified in which addition of local treatment of metachronous metastases can be considered.Aim. To improve the results of treatment of patients with mHSPC.Materials and methods. The prospective single-center cohort study included patients with metachronous mHSPC oligometastases (≤5) in the bones and nonregional lymph who were treated at the N.N. Blokhin National Medical Research Center of Oncology. Metastasis-directed therapy consisted of stereotactic body radiation therapy with total dose of 27–35 Gy (3–5 fractions). The primary endpoint was 6-month recurrence-free survival (RFS), the secondary endpoints were median RFS and local control.Results. Between 2017 and 2023, 38 patients were treated with median follow-up of 18 (3–79) months. Six-month RFS was 84.2 %, median RFS was 15 (3–62) months, local control was achieved in all 100 % of patients.Conclusion. Stereotactic body radiation therapy is a promising approach to the treatment of patients with metachronous mHSPC oligometastases. However, determination of the true place and role of this method in treatment schemes for patients of this category requires further studies including randomized phase III trials.
- 1 December 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (4) , 55-59
Open AccessMetastasis-directed therapy for metachronous metastases of prostate cancer
Background. The main method of treatment of metastatic hormone-sensitive prostate cancer (mHSPC) is drug therapy (hormone therapy, chemotherapy). However, a special category of patients with oligometastatic lesions can be identified in which addition of local treatment of metachronous metastases can be considered.Aim. To improve the results of treatment of patients with mHSPC.Materials and methods. The prospective single-center cohort study included patients with metachronous mHSPC oligometastases (≤5) in the bones and nonregional lymph who were treated at the N.N. Blokhin National Medical Research Center of Oncology. Metastasis-directed therapy consisted of stereotactic body radiation therapy with total dose of 27–35 Gy (3–5 fractions). The primary endpoint was 6-month recurrence-free survival (RFS), the secondary endpoints were median RFS and local control.Results. Between 2017 and 2023, 38 patients were treated with median follow-up of 18 (3–79) months. Six-month RFS was 84.2 %, median RFS was 15 (3–62) months, local control was achieved in all 100 % of patients.Conclusion. Stereotactic body radiation therapy is a promising approach to the treatment of patients with metachronous mHSPC oligometastases. However, determination of the true place and role of this method in treatment schemes for patients of this category requires further studies including randomized phase III trials.
- Open Access
- 29 December 2023
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 19 (4) , 119-124-124
Organ-preserving surgical treatment of a patient with synchronous bilateral morphologically different renal cell carcinoma, inferior vena cava tumor thrombus and pyeloureteral segment stone: clinical case
Kidney cancer is the 3rd most common disease in oncological urology. In 4–10 % cases, tumor thrombus of the inferior vena cava is diagnosed. In literature, single-digit number of cases of organ-preserving surgical treatment of patients with kidney cancer complicated by tumor thrombus is described. The article presents a rare clinical case of synchronous bilateral morphologically different kidney cancer with tumor thrombus in the left renal vein, perirenal segment of the inferior vena cava, pyeloureteral segment stone in the right ureter.
- 29 December 2023
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 19 (4) , 119-124-124
Open AccessOrgan-preserving surgical treatment of a patient with synchronous bilateral morphologically different renal cell carcinoma, inferior vena cava tumor thrombus and pyeloureteral segment stone: clinical case
Kidney cancer is the 3rd most common disease in oncological urology. In 4–10 % cases, tumor thrombus of the inferior vena cava is diagnosed. In literature, single-digit number of cases of organ-preserving surgical treatment of patients with kidney cancer complicated by tumor thrombus is described. The article presents a rare clinical case of synchronous bilateral morphologically different kidney cancer with tumor thrombus in the left renal vein, perirenal segment of the inferior vena cava, pyeloureteral segment stone in the right ureter.